Skip to Content
Merck

A4978

Alendronate sodium trihydrate

≥97% (NMR), bone resorption inhibitor, powder

Synonym(s):

4-amino-1-hydroxy-1-phosphonobutyl phosphonic acid, monosodium, MK-217

Sign In to View Organizational & Contract Pricing.

Select a Size

About This Item

Empirical Formula (Hill Notation):
C4H12NaNO7P2 · 3 H2O
CAS Number:
121268-17-5
Molecular Weight:
325.12
UNSPSC Code:
41106300
PubChem Substance ID:
24724391
NACRES:
NA.77
MDL number:
MFCD01748233
Assay:
≥97% (NMR)
Form:
powder
Quality level:
100

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

Alendronate sodium trihydrate, ≥97% (NMR), powder

SMILES string

[Na+].[H]O[H].[H]O[H].[H]O[H].NCCCC(O)(P(O)(O)=O)P(O)([O-])=O

InChI key

DCSBSVSZJRSITC-UHFFFAOYSA-M

InChI

1S/C4H13NO7P2.Na.3H2O/c5-3-1-2-4(6,13(7,8)9)14(10,11)12;;;;/h6H,1-3,5H2,(H2,7,8,9)(H2,10,11,12);;3*1H2/q;+1;;;/p-1

assay

≥97% (NMR)

form

powder

color

white

solubility

water, double-distilled: 10 mg/mL

storage temp.

−20°C

Quality Level

100

Gene Information

human ... FDPS(2224)

Related Categories

Application

Alendronate sodium trihydrate has been used:
  • for calcium phosphate nanoparticles (nCaP)/ bisphosphonate (BP) coating on titanium implants and analyze its osteogenic capacity
  • in osteogenic differentiation of human bone marrow stromal cells (hBMSCs) isolated from aged osteoporosis patients- and healthy-person
  • to treat osteoblast progenitor cells and osteoblasts and study their effect on osteoblast behaviors using conventional assays and simple digital image analysis

Biochem/physiol Actions

Alendronate is a nitrogen-containing bisphosphonate that is known to hinder the mevalonate pathway and limit osteoclastic function and activity. Alendronate sodium trihydrate is a bone resorption inhibitor, farnesyl diphosphate synthase inhibitor, and CD45 protein tyrosine phosphatase inhibitor.
Alendronate sodium trihydrate is a bone resorption inhibitor; farnesyl diphosphate synthase inhibitor (IC50 = 460 nM); CD45 protein tyrosine phosphatase inhibitor.

Preparation Note

Following reconstitution, it is recommended to aliquot and freeze at -20°C. Stock solutions are stable for up to 6 months at -20°C.

pictograms

Exclamation mark
GHS07

signalword

Warning

hcodes

H302

Hazard Classifications

Acute Tox. 4 Oral

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

dust mask type N95 (US), Eyeshields, Gloves

Regulatory Listings

Regulatory Listings are mainly provided for chemical products. Only limited information can be provided here for non-chemical products. No entry means none of the components are listed. It is the user’s obligation to ensure the safe and legal use of the product.

A4978-100MG: + A4978-VAR: + A4978-BULK:

jan

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000392826
0000341590
0000341590
0000392826
0000159966

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Núria Guañabens et al.
Hepatology (Baltimore, Md.), 58(6), 2070-2078 (2013-05-21)
Osteoporosis resulting in bone fractures is a complication in patients with primary biliary cirrhosis (PBC). Once-weekly alendronate improves bone mass and is well tolerated in these patients, but there is a concern because of poor compliance. Therefore, the efficacy, adherence
Songsong Zhu et al.
Bone, 53(2), 340-349 (2013-01-08)
Osteoporosis (OP) and osteoarthritis (OA) are major health problems in the increasing elderly population, particularly in postmenopausal women, but their relationship remains unclear. The present study investigated whether alendronate (ALN), a potent inhibitor of bone resorption, could protect articular cartilage
Jaishree Garhyan et al.
Pathogens (Basel, Switzerland), 9(5) (2020-05-18)
One-third of the world's population is estimated to be latently infected with Mycobacterium tuberculosis (Mtb). Recently, we found that dormant Mtb hides in bone marrow mesenchymal stem cells (BM-MSCs) post-chemotherapy in mice model and in clinical subjects. It is known
J Dennis Bobyn et al.
Clinical orthopaedics and related research, 472(2), 687-694 (2013-07-03)
Fixation of cementless orthopaedic implants is not always achieved, particularly in challenging scenarios such as revision surgery, trauma, and tumor reconstruction. An adjunct therapy for improving implant fixation would improve the reliability and durability of certain reconstructive procedures. The purpose
Osama Hussein et al.
Bone, 48(2), 202-211 (2010-09-21)
Breast cancer metastasizes to bone where it stimulates formation of bone-resorbing osteoclasts. Bisphosphonates constitute an important treatment for osteolytic metastases. The goal of this study was to assess the effects of soluble factors produced by breast cancer cells on osteoclast
View All Related Papers

Articles

Discover Bioactive Small Molecules for Lipid Signaling Research

Discover Bioactive Small Molecules for Lipid Signaling Research

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service